Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,108 | 68 | 92.0% |
| Education | $95.88 | 2 | 8.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $272.62 | 17 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $221.51 | 8 | $0 (2024) |
| Relypsa, Inc. | $92.00 | 6 | $0 (2020) |
| Aurinia Pharma U.S., Inc. | $88.66 | 5 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $81.42 | 5 | $0 (2019) |
| Amgen Inc. | $62.51 | 4 | $0 (2022) |
| GlaxoSmithKline, LLC. | $53.98 | 3 | $0 (2023) |
| Mallinckrodt LLC | $51.47 | 3 | $0 (2018) |
| Genentech USA, Inc. | $45.37 | 3 | $0 (2019) |
| Lilly USA, LLC | $39.23 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $111.78 | 7 | Lilly USA, LLC ($39.23) |
| 2023 | $127.71 | 8 | AstraZeneca Pharmaceuticals LP ($60.27) |
| 2022 | $170.88 | 10 | Aurinia Pharma U.S., Inc. ($58.50) |
| 2021 | $196.17 | 7 | Otsuka America Pharmaceutical, Inc. ($112.09) |
| 2020 | $122.95 | 8 | AstraZeneca Pharmaceuticals LP ($76.58) |
| 2019 | $267.24 | 18 | AstraZeneca Pharmaceuticals LP ($67.59) |
| 2018 | $152.48 | 9 | Mallinckrodt LLC ($51.47) |
| 2017 | $54.32 | 3 | Novartis Pharmaceuticals Corporation ($23.33) |
All Payment Transactions
70 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/07/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: NEPHROLOGY | ||||||
| 09/30/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.21 | General |
| Category: Diabetes | ||||||
| 09/18/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/06/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $0.37 | General |
| 06/10/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $18.55 | General |
| Category: NEPHROLOGY | ||||||
| 04/23/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/21/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.02 | General |
| Category: Diabetes | ||||||
| 07/13/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/22/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: IMMUNOLOGY | ||||||
| 05/22/2023 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $18.39 | General |
| Category: NEPHROLOGY | ||||||
| 04/27/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/13/2023 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/27/2023 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 01/31/2023 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/16/2023 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/16/2022 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: NEPHROLOGY | ||||||
| 10/26/2022 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $12.97 | General |
| Category: Inflammation | ||||||
| 08/15/2022 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $14.31 | General |
| Category: KRYSTEXXA | ||||||
| 07/11/2022 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: NEPHROLOGY | ||||||
| 06/20/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 05/24/2022 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: NEPHROLOGY | ||||||
| 05/05/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/03/2022 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: IMMUNOLOGY | ||||||
| 03/29/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 03/03/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $18.11 | General |
| Category: LUPUS NEPHRITIS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 36 | 4,412 | 7,009 | $2.7M | $366,841 |
| 2022 | 35 | 4,127 | 6,845 | $1.1M | $327,131 |
| 2021 | 40 | 5,743 | 9,152 | $1.4M | $408,177 |
| 2020 | 42 | 6,088 | 9,957 | $1.6M | $416,000 |
All Medicare Procedures & Services
153 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 52 | 365 | $715,254 | $95,842 | 13.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 245 | 712 | $470,817 | $63,221 | 13.4% |
| 93975 | Complete ultrasound of abdomen and pelvis artery and vein blood flow | Office | 2023 | 323 | 327 | $467,309 | $58,941 | 12.6% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 401 | 412 | $243,072 | $32,132 | 13.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 236 | 366 | $256,954 | $29,862 | 11.6% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 159 | 202 | $50,031 | $8,135 | 16.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 67 | 68 | $65,549 | $8,122 | 12.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 67 | 69 | $49,750 | $6,819 | 13.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 61 | 113 | $49,657 | $6,416 | 12.9% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 46 | 91 | $36,205 | $4,908 | 13.6% |
| 82306 | Vitamin d-3 level | Office | 2023 | 136 | 168 | $29,837 | $4,848 | 16.2% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 26 | 97 | $33,354 | $4,382 | 13.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 238 | 405 | $25,661 | $4,174 | 16.3% |
| 82610 | Cystatin c (enzyme inhibitor) level | Office | 2023 | 169 | 224 | $24,891 | $4,066 | 16.3% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 28 | 109 | $28,907 | $3,776 | 13.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 251 | 423 | $7,599 | $3,548 | 46.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 246 | 394 | $18,368 | $2,992 | 16.3% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 164 | 164 | $16,452 | $2,757 | 16.8% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 20 | 76 | $19,891 | $2,570 | 12.9% |
| 82043 | Urine microalbumin (protein) level | Office | 2023 | 253 | 400 | $11,895 | $2,259 | 19.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 19 | 19 | $17,358 | $2,254 | 13.0% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 242 | 382 | $11,873 | $1,936 | 16.3% |
| 93976 | Ultrasound of abdomen and pelvis artery and vein blood flow | Office | 2023 | 17 | 18 | $14,139 | $1,797 | 12.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 14 | $13,799 | $1,756 | 12.7% |
| 84100 | Phosphate level | Office | 2023 | 229 | 368 | $10,466 | $1,707 | 16.3% |
About Dr. Nathan Chamberlain, M.D
Dr. Nathan Chamberlain, M.D is a Nephrology healthcare provider based in Chattanooga, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2005. The National Provider Identifier (NPI) number assigned to this provider is 1134126246.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nathan Chamberlain, M.D has received a total of $1,204 in payments from pharmaceutical and medical device companies, with $111.78 received in 2024. These payments were reported across 70 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($1,108).
As a Medicare-enrolled provider, Chamberlain has provided services to 20,370 Medicare beneficiaries, totaling 32,963 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 153 distinct procedure/service records.
Practice Information
- Specialty Nephrology
- Other Specialties Nephrology
- Location Chattanooga, TN
- Active Since 07/05/2005
- Last Updated 05/28/2010
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1134126246
Products in Payments
- JYNARQUE (Drug) $221.51
- LOKELMA (Drug) $172.10
- Veltassa (Drug) $92.00
- LUPKYNIS (Drug) $88.66
- FARXIGA (Drug) $83.98
- ACTHAR (Biological) $66.08
- BENLYSTA (Biological) $53.98
- XARELTO (Drug) $49.47
- Rituxan (Biological) $45.37
- Auryxia (Drug) $40.39
- JARDIANCE (Drug) $39.23
- Parsabiv (Biological) $35.45
- INVOKANA (Drug) $31.95
- ENTRESTO (Drug) $23.33
- AURYXIA (Drug) $19.00
- BRILINTA (Drug) $16.54
- ULTOMIRIS (Drug) $14.71
- KRYSTEXXA (Biological) $14.31
- Parsabiv (Drug) $14.09
- Rayaldee (Drug) $12.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Chattanooga
Rohit Gupta, M.d, M.D
Nephrology — Payments: $10,529
Hans Yehnert, Md, MD
Nephrology — Payments: $5,326
Nilesh Patel, M.d, M.D
Nephrology — Payments: $3,184
John Mccarley, M.d, M.D
Nephrology — Payments: $2,939
Brant Holt, Md, MD
Nephrology — Payments: $2,929
Mandeep Grewal, Md, MD
Nephrology — Payments: $2,449